Long Daniel D. sold $115K of SEPN
Long Daniel D. (SVP, Drug Discovery) sold 3,334 shares of Septerna, Inc. (SEPN) at an average of $34.47 ($33.98–$34.68, $0.11M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific Aug. 3 open-market sale size, price range, and post-transaction holdings by an SVP, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment monitoring, but there is no accompanying fundamental update in the text.
What to watch
The filing does not include any new company-specific operational or clinical catalyst, so the only tradable element is potential short-term sentiment from insider activity.
Background
The article is a SEC Form 4 insider transaction disclosure for Septerna, Inc. (SEPN).
Ticker impact
Septerna (SEPN) disclosed an insider open-market sale by SVP Drug Discovery Long Daniel D. totaling about $114.9K on Aug. 3 under a 10b5-1 plan.
Low likelihood of a sustained price move from this filing alone; any impact would be sentiment-driven and short-lived.
Form 4 details a small-to-moderate value sale relative to typical market cap context, explicitly tied to a pre-arranged 10b5-1 plan, which generally reduces interpretive weight versus discretionary selling.
Market effects
No sector-level read-through is provided beyond routine insider activity at a biotech drug-discovery company.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it for directional bias.
Key entities
- issuerSepterna, Inc.
Company subject of the Form 4 insider transaction disclosure.
- insiderLong Daniel D.
SVP, Drug Discovery who sold shares via an open-market sale under a 10b5-1 plan.